Futures
Accédez à des centaines de contrats perpétuels
TradFi
Or
Une plateforme pour les actifs mondiaux
Options
Hot
Tradez des options classiques de style européen
Compte unifié
Maximiser l'efficacité de votre capital
Trading démo
Introduction au trading futures
Préparez-vous à trader des contrats futurs
Événements futures
Participez aux événements et gagnez
Demo Trading
Utiliser des fonds virtuels pour faire l'expérience du trading sans risque
Lancer
CandyDrop
Collecte des candies pour obtenir des airdrops
Launchpool
Staking rapide, Gagnez de potentiels nouveaux jetons
HODLer Airdrop
Conservez des GT et recevez d'énormes airdrops gratuitement
Pre-IPOs
Accédez à l'intégralité des introductions en bourse mondiales
Points Alpha
Tradez on-chain et gagnez des airdrops
Points Futures
Gagnez des points Futures et réclamez vos récompenses d’airdrop.
Investissement
Simple Earn
Gagner des intérêts avec des jetons inutilisés
Investissement automatique
Auto-invest régulier
Double investissement
Profitez de la volatilité du marché
Staking souple
Gagnez des récompenses grâce au staking flexible
Prêt Crypto
0 Fees
Mettre en gage un crypto pour en emprunter une autre
Centre de prêts
Centre de prêts intégré
仙乐 santé répond à la vérification de “优思益” : ne participe pas à la vente ou à la promotion, aucune relation liée, il s'agit d'un problème de marketing de marque isolé.
Capital Red Star, April 7, reported that in the early hours of the 7th, Xianle Health (300791.SZ), the domestic contract manufacturer of the “Australia Useevee” product, released a self-check situation statement.
“The current self-check situation is as follows: the food export order business that Xianle Health previously cooperated with the Australian enterprise ‘YARRA VIBE PTY LTD’ is production organized by Xianle Health in accordance with the contract and completion of export delivery; Xianle Health does not participate in the product sales, promotion, or marketing stages for that Australian customer, and has not granted any authorization for the related conduct. There is no affiliation, control relationship, or other interest relationship between Xianle Health and Guangzhou Yarra Source Health Industry Co., Ltd.” the statement said.
Xianle Health said that the current incident is an issue related to a specific brand’s marketing, and does not involve systematic risks in the production and manufacturing stage. The company’s quality system, compliance capabilities, and delivery capabilities remain stable.
On the morning of April 7, regarding issues such as background verification of the cooperation counterparty and whether there are other contract-manufactured products for cooperation, Capital Red Star reporters called Xianle Health’s office of the board secretary and sent an interview request; as of the time of publication, no response had been received.
On April 1, according to a report by CCTV News, the “Australia” identity of the eye-care lutein supplement product “Australia Useevee,” which was recommended by multiple celebrities, remained unclear. The product allegedly fabricates an overseas production location and forges its brand background; the so-called Melbourne factory is actually a car repair shop; the product is actually produced by a domestic contract manufacturer, and the domestic contract manufacturer is Xianle Health Technology (Anhui) Co., Ltd. The Useevee official website shows that its operator in China is Guangzhou Yarra Source Health Industry Co., Ltd.
In response, Australia Useevee released a statement saying that the Melbourne, Australia address mentioned in the CCTV report is the registered address of the brand holder YARRA VIBE PTY LTD; currently, Useevee’s office address in Australia is in the process of being changed, and the brand party will sublease the self-owned property to a car repair shop.
Capital Red Star noted that Xianle Health Technology (Anhui) Co., Ltd. is a wholly owned subsidiary of Xianle Health.
Public information shows that Xianle Health has seven major production bases and five research and development centers in China, Europe, and the United States, providing product development and production services for many nutrition and health food enterprises worldwide. Its business covers health supplements, functional foods, and special dietary foods.
In the first half of 2025, Xianle Health’s revenue was 2.04 billion yuan, of which the overseas market accounted for 60%.
Xianle Health’s 2025 performance pre-announcement shows that its net profit for 2025 is approximately 101 million to 151 million yuan, representing a year-on-year decrease of about 53% to 69%.
Reporter of Capital Red Star News: Jiang Ziwen
Editor: Xiao Ziqi
Reviewer: He Xianju